In A Study of Olezarsen Administered to Patients With Familial Chylomicronemia Syndrome (BALANCE), 66 patients with genetically confirmed FCS (homozygous or heterozygous compound loss function mutations in the genes for LPL, apoC2, apoA5, LMF-1 , or GPIHBP1 ) and fasting TG 880 mg/dl ( 10 mmol/l) were randomized to receive placebo or olezarsen at 50 or 80 mg monthly [106]
Athletes might face additional side effects relating to sport performance
17, 2026: Foundayo: FDA Requests More Safety Data for Wegovy Alternative GLP-1 Pill Apr
After subcutaneous injection, it forms microprecipitates in the tissue that slowly release insulin over approximately 24 hours, providing a relatively constant insulin level without pronounced peaks
The European ME/CFS biomarker landscape project: an initiative of the European network EUROMENE
Overall risk of bias for the primary outcome was low in all studies